Related references
Note: Only part of the references are listed.ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1
Zhuoxun Wu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2022)
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan et al.
ACTA PHARMACEUTICA SINICA B (2021)
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer et al.
LANCET ONCOLOGY (2021)
Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells
Zhuo-Xun Wu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens
Shumei Kato et al.
JCI INSIGHT (2021)
OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
Yuqi Yang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Overexpression of ABCC1 Confers Drug Resistance to Betulin
Xuan-Yu Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Tumour Microenvironment Stress Promotes the Development of Drug Resistance
Nicole A. Seebacher et al.
ANTIOXIDANTS (2021)
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Christiana M. Neophytou et al.
CANCERS (2021)
Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells
Zi-Ning Lei et al.
MEDCOMM (2021)
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance
Silpa Narayanan et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)
Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor
Liu-Ya Wei et al.
EXPERIMENTAL CELL RESEARCH (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
Lei Zhang et al.
MOLECULAR CANCER (2020)
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Zhuo-Xun Wu et al.
CANCERS (2020)
Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
Jingqiu Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Conversion of chemical to mechanical energy by the nucleotide binding domains of ABCB1
Daniel Szoellosi et al.
SCIENTIFIC REPORTS (2020)
Long non-coding RNAs regulate drug resistance in cancer
Kaisheng Liu et al.
MOLECULAR CANCER (2020)
Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells
Zhuo-Xun Wu et al.
CANCER SCIENCE (2020)
Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
Ales Sorf et al.
CANCERS (2020)
Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1-and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells
Yi-Dong Li et al.
FRONTIERS IN ONCOLOGY (2020)
Modulating the function of ABCB1:in vitroandin vivocharacterization of sitravatinib, a tyrosine kinase inhibitor
Yuqi Yang et al.
CANCER COMMUNICATIONS (2020)
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Nir Shahar et al.
DRUG RESISTANCE UPDATES (2020)
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin et al.
DRUG RESISTANCE UPDATES (2020)
Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
Yongchao Zhang et al.
CANCERS (2020)
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
Chodimella Chandrasekhar et al.
SCIENTIFIC REPORTS (2019)
Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors
Reza Dastvan et al.
SCIENCE (2019)
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
Qingbin Cui et al.
FRONTIERS IN ONCOLOGY (2019)
Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
Zhuo-Xun Wu et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
Thomas Boyer et al.
CANCERS (2019)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
L. Malorni et al.
ANNALS OF ONCOLOGY (2018)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2018)
Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR
Imran Shair Mohammad et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
Shaocong Wu et al.
MOLECULAR CANCER (2018)
Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling
Fei Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Structural insights into the functional diversity of the CDK-cyclin family
Daniel J. Wood et al.
OPEN BIOLOGY (2018)
Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview
Veronica Salmaso et al.
FRONTIERS IN PHARMACOLOGY (2018)
Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance
Ning Ji et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui et al.
DRUG RESISTANCE UPDATES (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robert W. Robey et al.
NATURE REVIEWS CANCER (2018)
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss
Yan Gao et al.
CELLULAR ONCOLOGY (2017)
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
N. Harbeck et al.
ANNALS OF ONCOLOGY (2016)
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Jamie I. Fletcher et al.
DRUG RESISTANCE UPDATES (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
M. Lienhard Schmitz et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
Mark C. de Gooijer et al.
INVESTIGATIONAL NEW DRUGS (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
Lars Anders et al.
CANCER CELL (2011)
Sildenafil Reverses ABCB1-and ABCG2-Mediated Chemotherapeutic Drug Resistance
Zhi Shi et al.
CANCER RESEARCH (2011)
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
Yan-jun Mi et al.
CANCER RESEARCH (2010)
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®
Robert W. Robey et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
S. -F. Zhou
XENOBIOTICA (2008)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
New inhibitors of ABCG2 identified by high-throughput screening
Curtis J. Henrich et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Erlotinib (Tarceva, OSI-774) antagonizes ATP-bInding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance
Zhi Shi et al.
CANCER RESEARCH (2007)
Inhibition of cyclin-dependent kinases - A review of the recent patent literature
Andrea D. Basso et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: Influence of cell line and modulator concentration on P-GP activity
ME Taub et al.
DRUG METABOLISM AND DISPOSITION (2005)
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
RW Robey et al.
BRITISH JOURNAL OF CANCER (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Share Paper
